Current medical research and opinionSep 9, 2026

Gallbladder disease risk with GLP-1 receptor agonists versus DPP-4 inhibitors in type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 10, 2026

Abstract

The risk of gallbladder disease in Type II diabetes patients treated with GLP-1RA is being assessed against those treated with DPP-4I.

Type II diabetes patients may experience varying risks of gallbladder disease depending on their medication.
GLP-1RA treatment is associated with potential gallbladder issues compared to DPP-4I.
The evaluation aims to confirm these risks in a specific patient population.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

GLP-1 drugs don't build habits — and that gap is costing patients their results

5 days ago7 studies

Semaglutide slowed aging and extended lifespan in older female mice

1 week ago7 studies

GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes

2 weeks ago7 studies

Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes

3 weeks ago7 studies

A once-daily pill beat placebo on weight loss — and it wasn't semaglutide

4 weeks ago7 studies

GLP-1 drugs work even without weight loss — and scientists are finally mapping why

5 weeks ago7 studies

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

6 weeks ago7 studies

The brain region that explains why blocking and activating the same receptor both cause weight loss

7 weeks ago7 studies

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

8 weeks ago7 studies

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief